199 related articles for article (PubMed ID: 24582495)
1. Blockage of CXCR2 suppresses tumor growth of intrahepatic cholangiocellular carcinoma.
Sueoka H; Hirano T; Uda Y; Iimuro Y; Yamanaka J; Fujimoto J
Surgery; 2014 Apr; 155(4):640-9. PubMed ID: 24582495
[TBL] [Abstract][Full Text] [Related]
2. High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery.
Shi RY; Yang XR; Shen QJ; Yang LX; Xu Y; Qiu SJ; Sun YF; Zhang X; Wang Z; Zhu K; Qin WX; Tang ZY; Fan J; Zhou J
Cancer; 2013 Mar; 119(5):993-1003. PubMed ID: 23132676
[TBL] [Abstract][Full Text] [Related]
3. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
[TBL] [Abstract][Full Text] [Related]
4. Calcium-sensing receptor promotes tumor proliferation and migration in human intrahepatic cholangiocarcinoma by targeting ERK signaling pathway.
Fang Y; Liu L; Liu S; Hu L; Cai W; Wan X; Liu D; He Y; Zhu Z
Eur J Pharmacol; 2020 Apr; 872():172915. PubMed ID: 31926993
[TBL] [Abstract][Full Text] [Related]
5. The prognostic significance and therapeutic potential of hedgehog signaling in intrahepatic cholangiocellular carcinoma.
Tang L; Tan YX; Jiang BG; Pan YF; Li SX; Yang GZ; Wang M; Wang Q; Zhang J; Zhou WP; Dong LW; Wang HY
Clin Cancer Res; 2013 Apr; 19(8):2014-24. PubMed ID: 23493353
[TBL] [Abstract][Full Text] [Related]
6. Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling.
Tang J; Liao Y; He S; Shi J; Peng L; Xu X; Xie F; Diao N; Huang J; Xie Q; Lin C; Luo X; Liao K; Ma J; Li J; Zhou D; Li Z; Xu J; Zhong C; Wang G; Bai L
J Transl Med; 2017 Nov; 15(1):238. PubMed ID: 29178939
[TBL] [Abstract][Full Text] [Related]
7. Decreased roundabout 1 expression promotes development of intrahepatic cholangiocarcinoma.
Mano Y; Aishima S; Fukuhara T; Tanaka Y; Kubo Y; Motomura T; Toshima T; Iguchi T; Shirabe K; Maehara Y; Oda Y
Hum Pathol; 2013 Nov; 44(11):2419-26. PubMed ID: 23953227
[TBL] [Abstract][Full Text] [Related]
8. FXR Acts as a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition.
Lv B; Ma L; Tang W; Huang P; Yang B; Wang L; Chen S; Gao Q; Zhang S; Xia J
Cell Physiol Biochem; 2018; 48(1):158-172. PubMed ID: 30001540
[TBL] [Abstract][Full Text] [Related]
9. IL-8/CXCR2 Signalling Promotes Cell Proliferation in Oesophageal Squamous Cell Carcinoma and Correlates With Poor Prognosis.
Inoue M; Takeuchi H; Matsuda S; Nishi T; Fukuda K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Kitagawa Y
Anticancer Res; 2021 Feb; 41(2):783-794. PubMed ID: 33517283
[TBL] [Abstract][Full Text] [Related]
10. Depletion of STYK1 inhibits intrahepatic cholangiocarcinoma development both in vitro and in vivo.
Chen MY; Zhang H; Jiang JX; Sun CY; Yu C; Tian S
Tumour Biol; 2016 Oct; 37(10):14173-14181. PubMed ID: 27542675
[TBL] [Abstract][Full Text] [Related]
11. High expression of protein tyrosine kinase 7 significantly associates with invasiveness and poor prognosis in intrahepatic cholangiocarcinoma.
Jin J; Ryu HS; Lee KB; Jang JJ
PLoS One; 2014; 9(2):e90247. PubMed ID: 24587299
[TBL] [Abstract][Full Text] [Related]
12. Hedgehog signaling between cancer cells and hepatic stellate cells in promoting cholangiocarcinoma.
Kim Y; Kim MO; Shin JS; Park SH; Kim SB; Kim J; Park SC; Han CJ; Ryu JK; Yoon YB; Kim YT
Ann Surg Oncol; 2014 Aug; 21(8):2684-98. PubMed ID: 24682719
[TBL] [Abstract][Full Text] [Related]
13. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type.
Shibahara H; Tamada S; Higashi M; Goto M; Batra SK; Hollingsworth MA; Imai K; Yonezawa S
Hepatology; 2004 Jan; 39(1):220-9. PubMed ID: 14752841
[TBL] [Abstract][Full Text] [Related]
14. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma.
Higashi M; Yonezawa S; Ho JJ; Tanaka S; Irimura T; Kim YS; Sato E
Hepatology; 1999 Dec; 30(6):1347-55. PubMed ID: 10573510
[TBL] [Abstract][Full Text] [Related]
15. Activation of CXCL5-CXCR2 axis promotes proliferation and accelerates G1 to S phase transition of papillary thyroid carcinoma cells and activates JNK and p38 pathways.
Cui D; Zhao Y; Xu J
Cancer Biol Ther; 2019; 20(5):608-616. PubMed ID: 30404567
[TBL] [Abstract][Full Text] [Related]
16. The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma.
Grépin R; Guyot M; Giuliano S; Boncompagni M; Ambrosetti D; Chamorey E; Scoazec JY; Negrier S; Simonnet H; Pagès G
Cancer Res; 2014 Feb; 74(3):873-83. PubMed ID: 24335961
[TBL] [Abstract][Full Text] [Related]
17. MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression.
Li J; Tian F; Li D; Chen J; Jiang P; Zheng S; Li X; Wang S
FEBS Lett; 2014 Sep; 588(18):3491-500. PubMed ID: 25131931
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II enhances epithelial-to-mesenchymal transition through the interaction between activated hepatic stellate cells and the stromal cell-derived factor-1/CXCR4 axis in intrahepatic cholangiocarcinoma.
Okamoto K; Tajima H; Nakanuma S; Sakai S; Makino I; Kinoshita J; Hayashi H; Nakamura K; Oyama K; Nakagawara H; Fujita H; Takamura H; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Harada S; Wakayama T; Iseki S; Ohta T
Int J Oncol; 2012 Aug; 41(2):573-82. PubMed ID: 22664794
[TBL] [Abstract][Full Text] [Related]
19. CXCR2 signaling might have a tumor-suppressive role in patients with cholangiocarcinoma.
Yamamoto Y; Sugimoto A; Maruo K; Tsujio G; Sera T; Kushiyama S; Nishimura S; Kuroda K; Togano S; Eguchi S; Tanaka R; Kimura K; Amano R; Ohira M; Yashiro M
PLoS One; 2022; 17(4):e0266027. PubMed ID: 35377900
[TBL] [Abstract][Full Text] [Related]
20. Aberrant expression of GATA binding protein 6 correlates with poor prognosis and promotes metastasis in cholangiocarcinoma.
Tian F; Li D; Chen J; Liu W; Cai L; Li J; Jiang P; Liu Z; Zhao X; Guo F; Li X; Wang S
Eur J Cancer; 2013 May; 49(7):1771-80. PubMed ID: 23313142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
